We synthesized and tested for biological activity eleven new PEGylated hGH derivatives. To this aim we used different strategies. A first group of PEGylable Cys derivatives was prepared by mutating into Cys single specific aminoacid residues located either in the connecting loop between helices 1 and 2 (Ile36 and Phe44) or in the connecting loop between helices 3 and 4 (Ile138 and Phe146). A second group of mutants was synthetized by inserting new Cys close to the aforementioned positions. Other PEGylable mutants were prepared by inserting a Gly4–Cys chain either at the N- or at the C-terminus of the hGH molecule. Finally, a Cys residue of the second hGH disulfide bond (Cys182–Cys189) was made available for PEGylation by mutating its companion Cys to open up the disulfide bridge. All these mutants were tested for their ability to affect Nb2 cell proliferation in vitro and showed different effects. Two mutations (Phe44Cys and +Cys47) severely impaired and two (Ile138Cys and Phe146Cys) increased hGH bioactivity. The mutation Cys189Ser was functionally silent whereas the remaining mutations caused a 15–50% decrease in activity. 20 kDa-pegylation caused a dramatic decrease in bioactivity in all mutants. The r-hGH-(Ile138Cys)–Cys138–PEG derivative showed the highest activity (15% of wild-type unpegylated hGH) and was selected for pharmacockinetic studies in vivo. It showed a fivefold longer half-life and was significantly more effective than wild-type hGH in causing weight gain when given subcutaneously twice a week to hypophysectomized rats.
In conclusion, even when it is directed to residues supposed to have a marginal role in the activity of this hormone, 20 kDa pegylation has detrimental effect on hGH bioactivity. These effects may be counterbalanced by the increase in half-life as it happens in pegylated Ile138Cys–hGH that could represent a promising new long-acting hGH derivative.
• Bedside: Current therapy of GH deficiency still has the important limitation of being delivered by daily subcutaneous injections and this reduces the compliance of the small pediatric patients. There is, therefore interest in developing long-acting GH derivative such as the new ones that we present here.
• Benchside: By investigating the effect of Cys substitutions at aminoacidic positions that had not been investigated in previous studies, we obtained evidence that Ile138 and Phe146 have a role in GH bioactivity in vitro.
• Industry: The mono-pegylated hGH mutant described in this work represents a promising candidate for human clinical pharmacology studies as long-acting derivative of h-GH.
• Community: By decreasing the frequency of GH injections, long acting GH could decrease the costs of GH treatment and increase medication adherence.
How to Cite:
Selis, F. et al., (2016). Preclinical characterization of eleven new Cys-PEGylated hGH mutants. New Horizons in Translational Medicine. 2(6-7), pp.147–154. DOI: http://doi.org/10.1016/j.nhtm.2015.12.002
Selis F, Genovese S, Salis B, Schrepfer R, Sblendorio V, Cataldi M, et al.. Preclinical characterization of eleven new Cys-PEGylated hGH mutants. New Horizons in Translational Medicine. 2016;2(6-7):147–54. DOI: http://doi.org/10.1016/j.nhtm.2015.12.002
Selis, F., Genovese, S., Salis, B., Schrepfer, R., Sblendorio, V., Cataldi, M., … Orsini, G. (2016). Preclinical characterization of eleven new Cys-PEGylated hGH mutants. New Horizons in Translational Medicine, 2(6-7), 147–154. DOI: http://doi.org/10.1016/j.nhtm.2015.12.002
Selis, Fabio, Stefano Genovese, Barbara Salis, Rodolfo Schrepfer, Valeriana Sblendorio, Mauro Cataldi, Giancarlo Tonon, and Gaetano Orsini. 2016. Preclinical characterization of eleven new Cys-PEGylated hGH mutants 2, no. 6-7: 147–154. DOI: http://doi.org/10.1016/j.nhtm.2015.12.002